- Home
- UNCY
as 05-08-2025 4:00pm EST
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | LOS ALTOS |
| Market Cap: | 71.8M | IPO Year: | 2021 |
| Target Price: | $5.50 | AVG Volume (30 days): | 510.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $1.16 | Next Earning Date: | 05-16-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1502.84% |
Latest Unicycive Therapeutics Inc. News
UNCY Breaking Stock News: Dive into UNCY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long
MT Newswires
18 days ago
Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target
GlobeNewswire
a month ago
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire
a month ago
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
a month ago
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
GlobeNewswire
3 months ago
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
GlobeNewswire
3 months ago
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Compare UNCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UNCY Unicycive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.